<DOC>
	<DOCNO>NCT02588534</DOCNO>
	<brief_summary>A single-center , open-label , randomize study screen period 21 day . Following , eligible men woman receive 50 mg etanercept subcutaneously thigh compare injection auto-injection device manual injection ( injection separate 28 day )</brief_summary>
	<brief_title>Open-label Study Using 50 Mg Liquid Etanercept Subcutaneous Injection Thigh Compare Auto-injector Device Manual Injection Healthy Subjects</brief_title>
	<detailed_description>A single-center , open-label , 2-period , 2-sequence , 2-treatment , randomize , crossover study . After screen period 21 day dose , 36 eligible men woman assign receive 50-mg subcutaneous ( SC ) dose etanercept administer 2 method injection ( Treatment A : administration auto-injector device ; Treatment B : administration manual injection ) separate occasion order determine randomization list ( randomized 1:1 sequence ) . Treatment administration separate minimum 28 day ( maximum 36 day ) . Subjects require remain resident 72-hours dosing period .</detailed_description>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Men woman age 18 45 year , inclusive time screen Body mass index ( BMI ) 19 30 kg/m2 , inclusive time screen Absence clinically significant physical examination finding determine investigator free clinically significant disease condition require care physician would interfere study evaluation procedure 12lead ECG ( report ventricular rate PR , QRS , QT QTc interval ) within normal limit clinically acceptable investigator Negative human immunodeficiency virus ( HIV ) antibody , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HepCAb ) status time screen Negative pregnancy test woman screen day dose Willing reside research facility 3 consecutive night , two occasion , willing return research facility schedule followup visit Before study specific procedure administration study medication , subject must sign Institutional Review Board ( IRB ) approve informed consent form Unstable medical condition , define hospitalize within 30 day , myocardial infarction within 6 month , major surgery within 6 month , seizure within 12 month study day 1 , otherwise unstable judgment investigator ( i.e. , risk complication adverse event unrelated study participation ) Clinically significant abnormality chemistry , hematology , urinalysis parameter perform screen determine investigator Current active infection , include chronic localized infection history recur infection underlie condition may predispose one infection ( e.g. , diabetes ) Known history active tuberculosis Donated blood blood product within 12 week day 1 , total 1500 mL within 1 year day 1 Known hypersensitivity etanercept excipients Use prescription overthecounter medication within 7 day day 1 without approval investigator ( exception vitamin , topical medication , contraceptive medication , hormonal replacement therapy postmenopausal woman ) Consumption alcohol within 48 hour dose Known history drug alcohol abuse within 1 year screen Positive urine screen alcohol and/or potential drug abuse , screen , day dose Smoked 10 cigarette per day within 12 month day 1 Women nurse lactate Unwilling unable practice adequate barrier method contraception ( e.g. , condom , barrier method contraceptive spermicide , IUD , etc . ) , determine investigator , duration study Use investigational agent , drug , and/or device within 30 day screen Any condition might reduce chance obtain data ( e.g. , know poor compliance ) require protocol might compromise ability give informed consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>etanercept , healthy subject , open-label , randomize , auto-injection , bioequivalence , pharmacokinetic</keyword>
</DOC>